Specialty Dosage Drugs

Lyndra, Thermo Fisher to Partner on R&D for Long-Acting Oral Therapies

January 15, 2025

The collaboration will leverage Thermo Fisher’s Accelerator Drug Development stable of solutions, which was launched in the fall of 2024.

First Nasal Spray for Anaphylaxis Approved by FDA

August 13, 2024

The epinephrine nasal spray was approved for the emergency treatment of type 1 allergic reactions in adults and children.

Finding a More Optimal Way for ATMPs (BIO 2024)

June 04, 2024

Pharm Tech Group looks at the challenges surrounding the development and manufacture of ATMPs in more detail with Agne Vaitkeviciene, CEO of Memel Biotech.

Biologics on Target for the Future

May 09, 2024

A greater understanding of molecular and cellular biology and technological advancements are revolutionizing the field of biologics.

Reshaping Dosage Forms

March 03, 2024

Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Frontrunners in Bispecific Antibodies

March 02, 2024

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

3D Printing Medicines with FABRX at CPHI Barcelona

November 02, 2023

Pharmaceutical Technology Europe® spoke with Carlos Rial Calvo from FABRX, a pharmaceutical 3D printing company, at the inaugural Start-Up Market on the show floor at CPHI Barcelona 2023.

Exploring Drug Storage, Drug Dosage, and the Supply Chain with Ulrike Lemke (DCAT Week)

May 12, 2023

Dr. Ulrike Lemke, Head of Sterile Fill Finish at Recipharm, sat down with Grant Playter, associate editor, to discuss drug delivery forms.

Frontrunner in Microbiome Therapeutics

March 03, 2023

EnteroBiotix is harnessing the power of the microbiome to target an array of diseases.

Inhaled Niclosamide Inhibits Viral Replication of the Omicron Variant of SARS-CoV-2

February 24, 2022

TFF Pharmaceuticals announces findings that inhaled niclosamide significantly inhibits viral replication of the Omicron variant of SARS-CoV-2.